Cullinan Therapeutics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome back, everyone. My name is David Dai. I am one of the biotechnology analysts here at UBS. Welcome to our inaugural UBS Healthcare Conference here in London. With us here today, we have Cullinan Therapeutics, and it is a great pleasure to have Nadim Ahmed, Chief Executive Officer, and also Jeff Jones, Chief Medical Officer, with us today. We are diving into some very interesting stuff that Cullinan is working on. Just for the audience here, Cullinan is a very interesting biotech company here. They have two pipeline programs right now. Actually, I would say three right now, right? With their CD19, they have two programs in autoimmune disease with their CD19 and BCMA T-cell engager. They also have one program for FLT3 T-cell engager targeting AML. We will dive into all these three programs today.
Maybe to start things off, Nadim, Jeff, just give a quick background of the overall story of Cullinan and the key programs we should be focusing on.
Sure. Great to be with you, David, back in my hometown, London. The first thing I would say is, you set it up nicely, we are very pleased to have what we would describe as a leading portfolio of T-cell engagers, clinical-stage T-cell engagers, across immunology and oncology, and we are heading into a very exciting period for the company over the coming weeks and months with multiple milestones. Starting with immunology, CLN-978 is our CD19 T-cell engager, which we are focusing in on rheumatic diseases, and more specifically, lupus, RA, and Sjögren's disease as our first indications. This is where we believe you need to deplete B cells more widely to exert its effect.
We presented the single target dose data earlier in the summer at EULAR, and in just a few weeks, we are looking forward to presenting our first initial multi-dose data, again, across all of those three indications. velinotamig is our BCMA T-cell engager. Our partner in China has started the first study in SLE. They presented very exciting data at ACR just this past week. With velinotamig, we are really focused in on those diseases that we believe are driven by plasma cells or long-lived plasma cells that are producing these pathogenic autoantibodies. Jeff and his team are in the process of kicking off our ex-China global development program with an initial basket phase I/II study in autoimmune cytopenias. On the oncology side, we have CLN-049. That is our FLT3 T-cell engager addressing AML.
We had a very positive end of phase I meeting with the FDA. We've started our pivotal study in relapsed/refractory AML. The study's active, we're recruiting patients. We're excited about that study and the data that's upcoming at ASH. Zipalertinib is not a T-cell engager, it's an oral tyrosine kinase inhibitor addressing exon 20 non-small cell lung cancer. We were very pleased just a few weeks ago to present the frontline data at the World Conference on Lung Cancer, where we saw the best PFS results we've seen in the frontline setting of exon 20, which we were very excited about. That's a program we're developing with our partners at Taiho Oncology. We just announced last week, we completed our first-line NDA submission to the FDA under the Real-Time Oncology Review process, or RTOR process.
The other aspect of zipalertinib is, for us, it's also a strategic asset in the sense that it is a source of near-term non-dilutive capital. We're owed regulatory milestones for the frontline and second-line indication approval in the U.S., as well as a 50/50 profit share in the U.S. That allows us to take those funds and put them back in to support our exciting T-cell engager program in immunology and oncology. I hope that provided you and the audience a snapshot of where we are.
This is a great background. Yeah, thank you, Nadim Ahmed, for all that. Let's dive into the CD19 BCMA T-cell engager first, which is, you have one dataset that's coming up, right, in 4Q, where you're going to show some additional data in repeat dose data for RA and SLE, lupus, as well as Sjögren's disease. It helps a level set that the competitive landscape overall, or treatment landscape, I would say, for rheumatology overall, right? Where do you see T-cell engager, you have two right now, CD3, BCMA, and/or CD19 T-cell engagers. Where do you see that fit into the current treatment landscape right now?
Sure. Jeff Jones can finish that one.
Yeah, sure. So, maybe first thinking about what is the current treatment landscape, and because we are talking about a lot of different diseases, maybe sort of think about it in a generic sense. So, most patients require immune suppression to control their symptoms, and that is delivered on a continuous basis. So once a patient has an established diagnosis, they go on some form of immune suppression, immune modulation, and they continue that in some form without interruption in many cases. So patients are constantly patients. What the prospect of novel therapies like T-cell engagers and the initial proof of concept data provided by CAR T suggests is that there is an opportunity to induce a deep remission that is sufficiently deep that it achieves a durable response without need for ongoing immune suppression.
That can deliver something really impactful for patients, which is what we, at least I think of as treatment-free time. Can you actually go for a period without having to take a tablet every day, an injection every week, an infusion every other month? And that is really the promise of a T-cell engager. So when we think about the two T-cell engagers in our portfolio, as you mentioned, David, we have both a CD19 and a BCMA. And in many of the common rheumatic diseases, B cells are really at the center of the pathophysiology. And there, we think that CD19 is probably the ideal target for a B cell-driven disease, because it has broad coverage of the B cell compartment, but generally leaves intact long-lived plasma cells that are responsible for memory humoral immune responses, including responses to vaccine.
So you can have a deep B cell-depleting effect that preserves a normal immune response, but potentially impact the disease in a way that delivers a treatment-free response. That is the promise of drugs like CLN-978.
Got you. Yeah, really, really helpful. And on the CD19 T-cell engager program, CLN-978, what are some differentiating features of that drug compared to other CD19 or CD20 T-cell engagers that we have seen from BLINCYTO or others?
Yeah, I think adding to what Jeff said, I think rheumatic diseases certainly seem to be a place, or many of them, where the disease is really driven probably by a pathogenic B cell, memory B cell, some other B cell. There, CD19, the advantage it has over CD20 is that it gives more breadth across the B cell compartment. So CD19 does more than what CD20 can do, and that's why we picked CD19 ahead of CD20. In terms of the specific molecular characteristics, so we engineered CLN-978 to have very high affinity for CD19. One, we believe that's good for taking out the B cells and depleting them deeply. Also, as you go further up the B cell lineage and compartment, you start to see CD19 expression start to dim. So the high affinity allows us actually to go further.
It allows us to get into probably plasmablasts, maybe short-lived plasma cells. So I think, again, it gives us that extended B cell coverage. We also have a molecule that has a very small size relative to many of the other CD19 T-cell engagers that are built on IgG backbones. So it's 150 kilodaltons for those molecules plus versus 65 kilodaltons for us, which we think could be important for penetration into tissue. So I think from a molecular differentiation perspective, that's important. I also think it's important to be first. I'm a commercial person. I would like to be first. Look, we presented the first company-sponsored data this summer for CD19 T-cell engager. We're about to present the multiple dose data in just a few weeks in December. That will then allow us in 2027 to expand into phase II and then registration studies beyond that.
I think we have a real opportunity now to take a differentiated molecule across multiple diseases, which I think is very exciting. I think the other thing that I would point out here is that some of these are very, very large diseases. So, there's room for more than one molecule here. Again, wanting to be first, but there is room for more than one molecule here. Certainly, the folk that are here from the U.S., you see those commercials every day in some of these large areas. So I think we're very pleased with where we are, both from an executional perspective, but also from a molecular differentiation perspective.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
